Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Miguel Forte

Miguel Forte

CEO, Zelluna Immunotherapy

Miguel Forte is the Chief Executive Officer of Zelluna Immunotherapy and currently Chief Commercialization Officer and Chair of the Commercialization Committee, International Society of Cellular Therapy. Formerly CMO, Bone Therapeutics SA and EVP and SVP of Clinical Development and Regulatory Affairs, COO and CMO of TxCell S.A. Miguel has extensive expertise in the regenerative medicine and cell therapy industries, as well as medical and regulatory affairs, ranging from leading early and late stage clinical trials to market authorization and the launch of new biologic products for various indications.

Notably, he contributed to TxCell’s transformation from a science based organization into a quoted cell therapy company, participating in several rounds of investment including the IPO of TxCell in 2014, and led multiple discussions, implementations and executions around major commercial and scientific partnerships. Held various senior positions at the European Medicines Agency, Bristol-Myers Squibb, Abbott and Wellcome Laboratories (now part of GSK), International Medical, Nabi Pharmaceuticals and UCB. Miguel has an M.D. (University of Lisbon), a Ph.D. in Immunology (University of Birmingham) and a Certificate on Health Economics of Pharmaceuticals (HEP) from the Stockholm School of Economics. He is also an Associate Professor in Health Sciences and Pharmacy at the University of Aveiro and the University of Lisbon and Fellow of the Faculty of Pharmaceutical Medicine of the RCP (UK).

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd